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Abstract
Background: Chronic kidney disease (CKD) is increasingly common and under-recognized in primary care clinics,
leading to low rates of stage-appropriate monitoring and treatment. Our objective was to determine whether
electronic problem list documentation of CKD is associated with monitoring and treatment.
Methods: This is a cross-sectional observational study of patients with stage 3 or 4 CKD, defined as two past
estimated glomerular filtration rates (eGFR) 15-60 mL/min/1.73 m
2 separated by 90 days and collected between
2007-2008. We examined the association of problem list documentation with: 1) serum eGFR monitoring test,
2) urine protein or albumin monitoring test, 3) an angiotensin converting enzyme inhibitor or angiotensin receptor
blocker (ACE/ARB) prescription, 4) mean systolic blood pressure (BP), and 5) BP control.
Results: Out of 3,149 patients with stage 3 or 4 CKD, only 16% of patients had CKD documented on the problem
list. After adjustment for eGFR, gender, and race/ethnicity and after clustering by physician, problem list
documentation of CKD was associated with serum eGFR testing (97% with problem list documentation vs. 94%
without problem list documentation, p= 0.02) and urine protein testing (47% with problem list documentation vs.
40% without problem list documentation, p= 0.04). After adjustment, problem list documentation was not
associated with ACE/ARB prescription, mean systolic BP, or BP control.
Conclusions: Documentation of CKD on the electronic problem list is rare. Patients with CKD documentation have
better stage-appropriate monitoring of the disease, but do not have higher rates of blood pressure treatment or
better blood pressure control. Interventions aimed at increasing documentation of CKD on the problem list may
improve stage-appropriate monitoring, but may not improve clinical outcomes.
Keywords: Electronic health record, Electronic problem list, Chronic kidney disease, Primary care,
Electronic medical record
Background
Chronic kidney disease (CKD) is prevalent in the United
States and successful approaches to treating the disease
could reduce healthcare costs and save lives. Ninety-five
percent of the 26 million Americans with CKD are in
the early stages of disease and are cared for in primary
care clinics by primary care physicians (PCPs) [1]. Nation-
ally accepted guidelines for CKD care describe several as-
pects of stage-appropriate monitoring and treatment that
can delay progression to end stage renal disease (ESRD).
Importantly, patients with albuminuria benefit from
angiotensin converting enzyme inhibitors (ACE) or
angiotensin receptor blockers (ARB) [2-5]. Blood pres-
sure (BP) control delays progression of CKD and pre-
vents mortality from common cardiovascular causes
[6,7]. The current state of primary care management of
early CKD is largely unknown, though there have been
reports of suboptimal management and low adoption of
CKD guidelines [8-10]. We do know that recognition of
CKD is low [8,11-14]. A systematic review revealed a wide
variation of CKD documentationi np a t i e n tr e c o r d s ;t h ea u -
thors compared CKD documentation to a gold standard of
estimated glomerular filtration rate and found sensitivities
ranged from 0.11-0.45 in the included studies [15]. We do
not know whether CKD documentation, and specifically
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quality of monitoring and treatment.
The electronic problem list in an electronic health rec-
ord (EHR, also known as EMR) is a specialized tool
which has been proven to improve the quality of care
for chronic conditions [16-18]. Seeing CKD on the prob-
lem list can remind the PCP to order appropriate tests
and medications, alert covering physicians to the condi-
tion, and trigger clinical decision support programs. For
these reasons, federal regulations on Meaningful Use in-
centives require use of an electronic problem list. We
sought to describe the association between problem list
documentation of CKD and quality of care for CKD.
Methods
Study population and setting
We first gathered data on all of the patients who visited
a primary care provider (PCP) at one of 12 primary care
clinics in the Brigham and Women’s Primary Care Prac-
tice Based Research Network. These clinics serve a di-
verse set of patients and include hospital-based and
community-based clinics, two of which are federally
qualified health centers. We included adult patients with
stage 3 or 4 CKD, defined as two past estimated glom-
erular filtration rates (eGFR) between 15-60 mL/min/
1.73 m
2, separated by 90 days and collected during rou-
tine clinical care between January 1, 2007 to December
31, 2008 [19]. Our laboratory routinely reports eGFR
calculated by the MDRD equation for all serum creatin-
ine measurements. Due to the low rate of testing for
urine protein in our population (see Results) we did not
include patients with proteinuria who had preserved
glomerular filtration rate. We limited the population to
patients who had at least one visit with a PCP at one of
the practices during 2009. The Partners Institutional
Review Board approved this study and granted waiver of
consent.
Electronic health record
The same EHR is used by all 12 clinics. The EHR is a
homegrown system called the Longitudinal Medical Rec-
ord which has been in use since July 2000 [20]. This
electronic record allows physicians to maintain problem
lists, medication lists, and allergy lists, view laboratory
results, enter notes and write electronic prescriptions.
Though specialists can add diagnoses to the problem
list, our prior work suggests that PCPs are currently
most likely to add diagnoses to the problem list [21].
When a provider types in a term that is related to a
renal disease, the EHR problem list module presents a
list of 15 renal diagnoses (e.g., kidney stones, polycystic
kidney disease, and renal cancer) that may be entered as
structured data. We obtained problem list entries through
a computerized search of electronic patient records for
the two codes which indicate CKD (Additional file 1, Lon-
gitudinal Medical Record codes 489 and 542). We vali-
dated this method with a manual chart review (Additional
file 1). At the time of this study there was no clinical de-
cision support to increase documentation of CKD on
the problem list [22]. There was a reminder for ACE/
ARB prescription for patients with CKD on the problem
list and two BP measurements >140/90 mmHg, and an-
other reminder prompted ACE/ARB prescription for
patients with serum creatinine >2.0 and two BP mea-
surements >130/80 mmHg.
Data analysis
We measured the proportion of patients who had CKD
documented on the EHR problem list. We also determined
the proportion of patients who had other renal diagnoses
on the problem list. We examined the association of poten-
tial confounders of the relationship between problem list
documentation and quality of care using the chi-squared
test. We included demographic characteristics (age, gender,
self-reported race/ethnicity) and we accounted for CKD
severity as a continuous variable by averaging two con-
secutive eGFR assessments 90 days apart. We could not
account for PCP demographic characteristics, but we ex-
amined PCP panels to determine the clustering pattern of
patients within panels.
We used similar methods to extract data on the five
outcomes of interest, while limiting the search to calen-
dar year 2009. We assessed the association of problem
list documentation with five stage-appropriate outcomes,
taken from nationally accepted guidelines: 1) serum
eGFR test (a measurement during the year 2009, in
addition to the two measurements from 2007-2008 used
to identify the CKD population), 2) urine albumin/pro-
tein test, 3) an ACE or ARB prescription, 4) mean sys-
tolic BP, and 5) BP control [6,19]. We accepted several
urine protein tests: urine total protein, microalbumin,
and microalbumin to creatinine ratio. We used medica-
tion list data for ACE/ARB prescription. We used the
last recorded blood pressure for blood pressure out-
comes and we examined two definitions of BP control:
130/80 mmHg and 140/90 mmHg. These outcomes
were chosen due to the strength of evidence for stage-
appropriate monitoring and treatment in stages 3 and 4
CKD, and therefore are considered “quality of care”
outcomes in the analysis. Due to the fact that PCPs may
not check urine albumin in patients who are already on
an ACE/ARB, we report the rate of testing in patients
who are not on an ACE/ARB. We also performed a sub-
group analysis of all outcomes on patients with diabetes
listed on the problem list for several reasons: 1) there is
evidence that ACE inhibitor therapy benefits CKD pa-
tients with proteinuria, but not necessarily CKD pa-
tients without proteinuria and 2) there is good evidence
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diabetes [23]. Referral to a nephrologist was not exam-
ined in a subgroup analysis due to incomplete data on
specialist referrals (Additional file 1).
We used multivariable logistic and linear regression to
adjust for confounders and to produce weighted estimates
(using the LSMEANS feature of the GENMOD procedure
in SAS, SAS Institute, Cary, NC). We first analyzed the data
assuming that each event was independent. Then we con-
ducted analyses accounting for clustering by PCP and
found similar results. All unadjusted and adjusted estimates
are presented after accounting for clustering by PCP.
Results
Patient characteristics
Of the 79,605 patients who made a visit to a PCP in
2009, there were 3,149 patients with stage 3 or 4 CKD
as defined by two eGFR results between 15-60 mL/min/
1.73 m
2 separated by 90 days. Patients had a mean age
of 74 years (range 26-104 years) and were predominantly
female (Table 1). The mean eGFR was 46 mL/min/
1.73 m
2 (standard deviation ±10 mL/min/1.73 m
2). Race/
ethnicity rates were 67% White, 23% Black, 8% Hispanic,
and 1.5% Asian.
Physician panel characteristics
Of the patients with a laboratory diagnosis of stage 3 or
4 CKD, 3,074 patients were assigned to one of the 269
PCPs within the Brigham and Women’s Primary Care
Practice Based Research Network. Each PCP panel in-
cluded 1 to 173 patients. We treated the 75 patients who
were not assigned to a PCP as independent clusters.
Problem list entry of chronic kidney disease
Out of 3,149 patients with laboratory evidence of stage 3
or 4 CKD, 488 patients (16%) had CKD on the problem
list. Problem list documentation was more likely in pa-
tients with lower eGFR, male gender, Black race/ethnicity,
or Hispanic race/ethnicity (Table 1). In terms of PCP
panels, the PCPs had between 1 and 16 patients with
CKD documented on the problem list (out of a total of 1
to 173 patients with laboratory evidence of stage 3 or 4
CKD). An additional 7% of patients with laboratory evi-
dence of stage 3 or 4 CKD had one of the other renal diag-
noses on the problem list (see Additional file 1).
Quality of care outcomes
We then sought to determine whether CKD documenta-
tion correlated with five quality of care outcomes during
calendar year 2009: 1) serum eGFR test, 2) urine protein
or albumin test, 3) an angiotensin converting enzyme in-
hibitor or angiotensin receptor blocker prescription, 4)
mean systolic blood pressure, and 5) blood pressure
control (separate analyses for goal <130/80 mmHg
and <140/90 mmHg). The percentage of patients with a
serum eGFR test during the one year study period was
94% and there was an association with CKD docu-
mentation after adjusting for clustering by PCP (CKD
documentation 98% vs. no CKD documentation 93%,
p<0.0001). A model adjusting for eGFR, gender, and
race/ethnicity, showed a significant association as well
(97% vs. 94%; p=0.02; Table 2). The overall rate of urine
protein or albumin testing was 40% and there was a sig-
nificant association with problem list documentation
(61% vs. 41%, p <0.0001), which persisted after adjust-
ment for eGFR, gender, and race (47% vs. 40%, p=0.04;
Table 2). The overall rate of ACE/ARB prescription was
65% and there was a significant association with problem
list documentation (75% vs. 66%, p <0.0001), but the asso-
ciation was no longer significant after adjustment for eGFR,
gender, and race (Table 2). The rate of urine protein or al-
bumin testing in patients who were not on an ACE/ARB
Table 1 Characteristics of stage 3 and 4 CKD patients in a network of primary care practices and association with
CKD documentation
Total
(N= 3149)
CKD on problem list
(N=488)
CKD not on problem list
(N=2661)
P value
Patient characteristics
Age, mean (SD) 73.6 (12.1) 73.9 (12.7) 73.6 (11.9) P =0.62
Female gender, N (%) 223 (64%) 229 (47%) 1809 (68%) P< 0.0001
eGFR, mean (SD) 45.9 (9.98) 37.6 (10.1) 47.5 (9.2) P< 0.0001
Race/Ethnicity, N (%) P=0.004
White 2064 (67%) 288 (60%) 1776 (68%)
Black 723 (23%) 138 (29%) 585 (22%)
Hispanic 260 (8.4%) 49 (10%) 211 (8%)
Asian 45 (1.5%) 8 (1.7%) 37 (1.5%)
Diabetes 866 (28%) 196 (40%) 670 (25%)
Hypertension 2118 (67%) 384 (79%) 1734 (65%)
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ciation with problem list documentation (48% vs. 22%, p<
0.0001). The mean BP of patients was 133/72 mmHg.
There were no significant associations between problem list
documentation and mean systolic BP or mean diastolic BP
before or after adjustment (Table 2). With a BP goal of 140/
90 mmHg, 71% were under control and the likelihood of
being under control was not associated with problem list
documentation (Table 2). With a blood pressure goal of
130/80 mmHg, 45% were under control and the likelihood
of being under control was not associated with problem list
documentation (Table 2).
In the subgroup of 866 patients with diabetes, the per-
centage of patients with a serum eGFR test during the one
year study period was 96% and there was an association
with CKD documentation (after adjusting for clustering
by PCP; CKD documentation 99% vs. no CKD documen-
tation 96%, p=0.05). However, the association was no lon-
ger significant after adjustment for eGFR, gender, and
race. The rate of urine protein or albumin testing in pa-
tients with diabetes was 77% and there was no significant
association with CKD problem list documentation. This is
compared to a rate of 26% in the 2283 patients without
diabetes, where there is a significant association of urine
protein or albumin testing with CKD documentation (44%
vs. 24%, p<0.0001), but the association was no longer sig-
nificant after adjustment for eGFR, gender, and race. The
rate of ACE/ARB prescription in patients with diabetes
was 86% and there was no significant association with
CKD problem list documentation. There were no signifi-
cant associations between CKD documentation and blood
pressure outcomes within the diabetes subgroup.
Discussion
We found that one out of every six patients with labora-
tory evidence of stage 3 or 4 CKD had CKD documented
as a diagnosis on the problem list. The low documentation
of this chronic illness shows that there are opportunities
to improve the quality of care for CKD patients. Docu-
mentation was associated with certain patient characteris-
tics such as disease severity, suggesting that there is a
severity threshold above which PCPs are more likely to
document CKD on the problem list.
We also found that demographic characteristics (i.e.,
male gender, Black race, and Hispanic ethnicity) are as-
sociated with CKD documentation, which is consistent
with prior studies. One possibility is that CKD docu-
mentation is more common in groups that have higher
serum creatinine levels for a given eGFR (men and Black
patients [24]); this fact may suggest that physicians are
still using the serum creatinine level to diagnose CKD.
However, patients of Hispanic ethnicity typically have
lower creatinine levels than white patients [25]. Therefore,
the relatively higher rate of CKD documentation in His-
panic patients would not be related to creatinine level.
Encouragingly, patients with CKD on the EHR pro-
blem list were more likely to receive stage-appropriate
monitoring including serum eGFR testing and urine pro-
tein testing. The higher rate of urine protein testing
is important because recent evidence and expert opinion
support the idea that urine protein testing in addition to
serum creatinine-based measures provide superior risk
stratification [26,27]. When we examined urine protein test-
ing in the diabetes subgroup, we did not see an association
with CKD documentation, which may be due to competing
demands in patients with multiple comorbidities [28].
We did not find a significant relationship between CKD
documentation and higher quality treatment, specifically
ACE/ARB treatment, after adjustment for age, race and
eGFR. Finally, the mean systolic and diastolic BP values
were not associated with CKD documentation and when
we examined BP control as a dichotomous outcome we
found that CKD documentation was not associated with
the likelihood of blood pressure control.
The low rate of documentation is in agreement with
studies that examined CKD documentation using billing
Table 2 Associations of CKD documentation with monitoring and treatment
Unadjusted estimates
a Adjusted estimates
ab
Total
(N= 2965)
CKD on
problem list
(N=488)
CKD not on
problem list
(N=2661)
p value CKD on
problem list
(N= 483)
CKD not on
problem list
(N=2623)
p value
Serum eGFR, % 94% 98% 93% P< 0.0001 97% 94% P =0.002
Urine protein, % 40% 61% 41% P< 0.0001 47% 40% P= 0.04
ACE/ARB, % 65% 75% 66% P< 0.0001 68% 67% P= 0.62
Systolic BP, mean 132.5 mmHg 132.4 mmHg 132.5 mmHg P=0.88 131.9 mmHg 132.1 mmHg P= 0.84
Diastolic BP, mean 72.0 mmHg 71.2 mmHg 72.1 mmHg P=0.12 72.3 mmHg 71.9 mmHg P= 0.50
BP <140/90 mmHg 71% 69% 72% P=0.22 72% 72% P= 0.99
BP <130/80 mmHg 45% 46% 45% P=0.74 46% 46% P= 0.86
aAdjusted for clustering by physician.
bWeighted estimates after adjustment for eGFR, gender, race.
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study which examined billing codes found that CKD was
included as a billing code only 14% of the time [14]. In a
study conducted within an integrated delivery system
CKD documentation was 24% and the investigators found
that male gender and Black race were significantly asso-
ciated with documentation, just as we did [29]. Another
study reported a combined electronic problem list and
billing diagnosis rate of 19% [30]. Interestingly, another
study examined clinic notes for patients with low eGFR
and reported a 70% rate of documentation in the text of
the clinic notes, suggesting that our study examining the
electronic problem list falls prey to the same limitations as
research using billing codes; neither one reflects true PCP
awareness of CKD [12]. However, we still support obser-
vation and intervention to improve the problem list be-
cause documentation in the free text of clinical notes is
not as useful for quality measurement, health services re-
search, or clinical decision support interventions, and po-
tentially is a barrier to team-based primary care models,
such as the patient-centered medical home.
The strength of this study of electronic problem list
documentation was the large dataset from the clinical
information system of a primary care network serving a
diverse population. Despite these strengths, our study has
several limitations. Though we utilized longitudinal data,
we analyzed the data in a cross-sectional fashion. There-
fore, we cannot assume that associations are causal in na-
ture. PCPs may choose not to add CKD as a separate
diagnosis when a patient already has a renal diagnosis (e.
g., polycystic kidneys). It is possible that certain PCPs
characteristics (e.g., thoroughness, visit duration, practice
style) confound the association between documentation
and quality of care, but we chose to cluster patients within
PCP panels for this reason. When considering limitations
of measures, data on laboratory tests was limited to those
performed in our hospital’s affiliated laboratories, but the
population only included patients who had seen one our
affiliated PCPs during the study period and all lab orders
are automatically routed through our central laboratory.
We attempted to control for severity of CKD by adjusting
for eGFR as a continuous measure, but this may not ac-
curately reflect severity of disease. Similarly, we only cap-
tured ACE/ARB prescriptions written using our electronic
prescribing module, but all PCPs were using this module
almost exclusively during the study period. We did not in-
clude serum creatinine tests unless an eGFR was reported
by the lab as well, but eGFR has been routinely reported
by our lab for the past decade. We used the last BP rea-
ding rather than a synthesis of multiple blood pressure
readings over the study period, which may affect the vali-
dity of the measure [31]. Due to the limitations of the
dataset, we do not know how severe the albuminuria was
for each patient. In terms of ACE/ARB prescription and
blood pressure control, the overlap between management
of CKD and management of both diabetes and hyperten-
sion limits our ability to distinguish any impact of CKD
documentation from interventions affecting diabetes and
hypertension management. We were unable to include
outcomes that would be specific to CKD, such as dose ad-
justment of nephrotoxic medications. These limitations
were introduced by the method of data collection which
relied on electronic data collected during routine care,
which is a low-cost, feasible approach to health services
research, and we have verified the validity of the data with
a manual chart review (Additional file 1).
Conclusion
Documentation of CKD on the electronic problem list was
uncommon and more likely in patients with certain demo-
graphic characteristics and more severe CKD. CKD docu-
mentation was positively associated with stage-appropriate
monitoring, both serum eGFR testing and urine protein
testing. However, CKD documentation was not associated
with higher rates of blood pressure treatment or better
blood pressure control. Therefore, interventions aimed at
increasing documentation of CKD can improve monitoring,
but documentation alone is not sufficient to improve treat-
ment or intermediate clinical outcomes.
Additional file
Additional file 1: A. Options provided within the electronic
medical record to add renal diagnoses to the problem list. B. Data
Validation study.
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